Sirolimus Treatment of an Infant With Intrathoracic Kaposiform Hemangioendothelioma Complicated by Life-threatening Pleural and Pericardial Effusions. by Duan, Lucy et al.
Sirolimus Treatment of an Infant With Intrathoracic
Kaposiform Hemangioendothelioma Complicated by
Life-threatening Pleural and Pericardial Effusions
Lucy Duan, MD,* Samuele Renzi, MD,† Danielle Weidman, MD,†
Nicolas Waespe, MD,†‡ Rose Chami, MD,§ David Manson, MD,∥
Michaela Cada, MD, MPH,† and Manuel Carcao, MD, MSc†
Summary: Kaposiform hemangioendothelioma (KHE) is a rare
inﬁltrative vascular tumor that may be associated with Kasabach-
Merritt Phenomenon (KMP), which is a consumptive coagulopathy
with potentially life-threatening thrombocytopenia. Management
of KHE and KMP is challenging, and currently, there are no
standardized validated treatment protocols. Mammalian target
of rapamycin inhibitors have been shown to be effective in the
treatment of KHE. We describe a term male who presented as a
diagnostic dilemma with life-threatening pleural and pericardial
effusions and severe thrombocytopenia. After extensive work-up the
etiology for his condition was determined to be KHE with KMP.
The patient was commenced on sirolimus and responded well to
therapy with resolution of KMP.
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K aposiform hemangioendothelioma (KHE) is a rarevascular, inﬁltrative tumor typically encountered in
infancy as a large (> 5 cm) cutaneous lesion with ill-deﬁned
borders located in the skin or soft tissue.1 KHE may spon-
taneously decrease in size with time, but complete regression
is uncommon.2 KHE are typically located in the neck,
axilla, groin, extremities, and trunk but can occur in non-
cutaneous locations including the bone, mediastinum, and
retroperitoneum. Lesions are usually solitary; however,
multifocal lesions have been reported.3,4 There are no
reports implicating underlying genetic mutations, sex, or
ethnicity bias in the etiology of KHE. Most cases present
within the ﬁrst 3 months of life with some cases diagnosed in
utero and others after several years of life.2,3
KHE may be associated with Kasabach-Merritt Phe-
nomenon (KMP), a potentially life-threatening consumptive
coagulopathy.5 Laboratory disturbances include profound
thrombocytopenia (< 50,000/μL) and hypoﬁbrinogenemia
with elevated markers of coagulation activation including
d-dimer and ﬁbrin degradation products.
Management of KHE associated with KMP can be
challenging and currently there are no standardized vali-
dated treatment protocols.6 Consensus derived ﬁrst-line
therapy for complicated KHE (eg, with pain, cellulitis,
ulcerations, visceral/bone involvement, or cardiac dys-
function) and KHE associated with KMP was developed in
2013 through a survey of 24 vascular anomaly centers
and a review of existing literature.6 First-line therapy
included vincristine with or without oral or intravenous
corticosteroids.6 Since 2013, mammalian target of rapa-
mycin (mTOR) inhibitors have been shown to be safe
and effective in the treatment of vascular tumors such as
KHE and even more recently in the treatment of vascular
malformations.7,8
We describe a newborn term male who presented as a
diagnostic dilemma with life-threatening pleural and peri-
cardial effusions and severe thrombocytopenia. A diagnosis
of KHE complicated by KMP was made and the patient
demonstrated partial response to oral sirolimus after several
weeks of treatment.
CASE REPORT
A full-term male neonate was born at 39 weeks gestation to a
26-year-old G2P0 mother. She was blood group B positive and had a
normal prenatal ultrasound at 20 weeks gestation. At 36 weeks
gestation, prenatal ultrasound showed polyhydramnios and the
fetus was found to have severe bilateral pleural effusions, left greater
than right, with mediastinal deviation. As a result, the fetus
underwent insertion of bilateral pleuroamniotic shunts in utero. The
baby was delivered with vacuum assistance after spontaneous rup-
ture of membranes; birth weight was 3.18 kg. There was meconium
present at delivery and APGAR scores were 7, 8, and 9 at 1, 5, and
10 minutes, respectively. Both pleuroamniotic shunts were clamped
at birth and removed at 3 minutes of life. The baby was admitted to
the neonatal intensive care unit. Initial examination demonstrated
a well-grown male infant with no dysmorphisms or cutaneous
anomalies.
On day 8 of life, a right-sided chest tube was inserted due to
reaccumulation of pleural effusion. Pleural ﬂuid analysis showed
chylous content. On day 16 of life, the chest tube drainage subsided,
and the chest tube was removed. On day 30 of life, the infant
developed increased work of breathing requiring transient con-
tinuous positive airway pressure. Once weaned back to room air, the
infant was transferred to a pediatric inpatient unit for further
investigation.
Complete blood count on day 1 of life showed a platelet count
of 157,000/μL, which dropped to 46,000/μL by day 15 of life and to
23,000/μL on day 23 of life. In addition to this gradually worsening
thrombocytopenia, there were increased reticulocytes, markedly
elevated lactate dehydrogenase of 2176U/L, and presence of
schistocytes (fragments) on the blood smear. There were signs of
a consumptive coagulopathic process including low ﬁbrinogen
Received for publication April 29, 2018; accepted June 22, 2018.
From the Departments of *Paediatrics; †Paediatrics, Division of Hae-
matology/Oncology; §Paediatric Laboratory Medicine; ∥Diagnostic
Imaging, The Hospital for Sick Children, Toronto, ON, Canada;
and ‡Swiss Childhood Cancer Registry, Institute of Social and
Preventive Medicine, University of Bern, Switzerland.
The authors declare no conﬂict of interest.
Reprints: Lucy Duan, MD, Department of Pediatrics, The Hospital for
Sick Children, 555 University Avenue, Toronto, ON, Canada M5G
1X8 (e-mail: lucy.duan@sickkids.ca).
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
CLINICAL AND LABORATORY OBSERVATIONS
J Pediatr Hematol Oncol  Volume 00, Number 00, ’’ 2018 www.jpho-online.com | 1
Copyright r 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
11
93
41
 
| 
do
wn
lo
ad
ed
: 
6.
1.
20
20
(0.8 g/L) and elevated d-dimer (> 4 μg/mL ﬁbrinogen equivalent
units). The patient required transfusions of multiple blood products
including platelets, fresh frozen plasma, and cryoprecipitate with
minimal improvement in the platelet count and coagulopathy.
The following investigations were normal: ADAMTS13
activity, neonatal alloimmune thrombocytopenia testing, HLA
antibody testing, and Noonan syndrome genetic testing. Echo-
cardiogram showed patent foramen ovale and closed ductus arte-
riosus. Ultrasounds of thyroid and abdomen did not show any
anomaly. Total-body magnetic resonance imaging (MRI) without
contrast was performed at 1 month of life to search for a vascular
malformation/tumor as a source of the consumptive coagulopathy,
and demonstrated pleural effusions and a small amount of ascites
with no vascular anomalies.
On the basis of the results of laboratory investigations
including thrombocytopenia, low ﬁbrinogen, elevated d-dimer, and
minimal response to platelet transfusions, there continued to be a
high clinical suspicion of KMP. As such, previous imaging was
repeated. This included an abdominal ultrasound in conjunction
with a spinal ultrasound to screen for intraspinal contents. This
revealed increased vascularity and hyperemia within the dorsal chest
wall musculature. A dedicated MRI (with contrast) of this area was
then performed, which revealed an extensive inﬁltrative vascular
lesion involving the bilateral paraspinal musculature, prevertebral
spaces, posterior extrapleural space, mediastinum, thymus, and
neck with intense arterial enhancement. The lesion encased the
thoracic aorta, great vessels, esophagus, thoracic trachea, and main-
stem bronchi. The precise size of the lesion was not reported due to
its extent and inﬁltrative nature (Figs. 1, 2A, B).
On the basis of the clinical and radiologic presentation, KHE
was presumed to be the most likely diagnosis. Biopsy was not ini-
tially performed due to bleeding risk. The patient was started on
prednisone (2 mg/kg/d) and oral sirolimus (0.8 mg/m2/dose twice
daily) on day 45 of life. There was no clinical or laboratory
improvement after the ﬁrst month of treatment, and the patient
continued to require weekly red blood cell transfusions and frequent
platelet transfusions. He developed recurrent bilateral pleural effu-
sions that required multiple admissions to the pediatric intensive
care unit for continuous positive airway pressure, and 6 chest tube
insertions with serosanguineous drainage. In addition, on day 79 of
life, he had pericardiocentesis with placement of a pericardial drain
for a large circumferential pericardial effusion with signs of early
tamponade. As his condition remained life-threatening and as he
did not initially appear to respond to therapy, a surgical biopsy of
the lesion was performed to rule out other potential entities. Biopsy
ﬁndings conﬁrmed the diagnosis of KHE (Figs. 3A–C). Histo-
pathologic features included inﬁltrating nodules, sheets of variably
spindled endothelial cells, focal immunopositivity for lymphatic
endothelial markers, nuclear atypia, microthrombi, hemosiderin
deposition, ﬁbrosis, and abnormal lymphatic channels. With con-
tinued treatment, the patient slowly began to improve and was well
enough for discharge from hospital at 3.5 months of life, was
transfusion independent, had no evidence of further effusions.
The infant continued on sirolimus at the same dose as an
outpatient, targeting blood levels of 5 to 15 μg/L. Prednisone was
weaned off at 4.5 months of life. A repeat MRI with contrast per-
formed after 7 months of sirolimus therapy showed signiﬁcant
reduction in the size of the original KHE (Fig. 4). The patient
continues on the same nominal dose of sirolimus, without adjust-
ments for weight gain. He is doing well clinically and will have a
repeat MRI after 2 years of sirolimus therapy. If the lesion con-
tinues to regress sirolimus will be slowly discontinued at that time.
DISCUSSION
We present a case of a newborn male with KMP sec-
ondary to intrathoracic KHE without cutaneous involve-
ment, complicated by prolonged pericardial and pleural
effusions leading to life-threatening respiratory complica-
tions. He had a good response to sirolimus therapy. Intra-
thoracic KHE is rare. In a large retrospective review of 107
patients with KHE at Boston Children’s Hospital only 9 of
the 107 patients had intrathoracic KHE.3 Compared with
superﬁcial lesions, intrathoracic KHE lesions are 18-fold
FIGURE 1. Curvilinear transducer with color Doppler image from
a posterior approach shows increased vascularity (arrows) to the
paraspinal dorsal muscle groups.
FIGURE 2. Pregadolinium-enhanced (A) and postgadolinium-enhanced (B) T1 fat-suppressed images show extensive enhancement
(arrows) throughout the posterior thoracic musculature. The enhancement pattern is lobulated, consistent with an infantile kaposiform
hemangioendothelioma.
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more likely to manifest KMP, and these patients usually
present with clinical respiratory distress.3 In addition, only
11% of all KHE have been reported to have no overlying
skin changes.3 Our patient’s clinical presentation was unique
in that the infant developed life-threatening pleural and
pericardial effusions, which are rare complications of
KMP.3,9 The mechanism of the development of pleural and
pericardial effusions is not completely understood, but given
the chylous content of the pleural ﬂuid, it was thought to be
secondary to blockage of lymphatic drainage by the mass.10
Platelet transfusions have been shown to be of minimal
beneﬁt in patients with KMP.6 In addition, platelets can be
retained within the KHE and result in enlargement of the
mass.11 This may have occurred in our patient before the
diagnosis of KHE being made. Our patient’s transfusion-
refractory thrombocytopenia and coagulopathy prompted
repeat MRI imaging—this time with contrast. This then
conﬁrmed the diagnosis. Once a diagnosis of KHE was
made, platelet transfusions were restricted to only surgical
procedures or in the case of bleeding.
MRI is the imaging modality of choice to demonstrate
and evaluate the extent of such masses.3 T2 weighted MRI
typically demonstrates a poorly marginated area of abnor-
mal increased T2 weighted signal, and tubular ﬂow voids of
the increased vascularity may be seen.3 Flow sensitive and
gadolinium-enhanced sequences can help to show the
increased vascularity. Whole body MRI without contrast
can miss even large lesions. This occurred in our case. Once
the diagnosis of KHE was made, the ﬁrst MRI (without
contrast) that failed to show the lesion was rereviewed.
Indeed, hyperintensity in the spinal musculature was seen
but this had initially been interpreted as compression arte-
facts due to the supine positioning of the child. Diagnosis of
KHE was ﬁnally suspected based on the characteristic
imaging ﬁndings by dedicated gadolinium-enhanced MRI of
the region of interest (Figs. 1/, 2A, B, 4) and a diagnosis was
conﬁrmed with histopathology (Figs. 3A–C).
Recently, a clinicopathologically distinct anomaly
kaposiform lymphangiomatosis (KLA) was described and is
characterized by clinical intrathoracic disease with effusions
and respiratory symptoms, as well as histologic ﬁndings of
spindled lymphatic endothelial cells.12 Our patient’s unique
presentation with pericardial and pleural effusions leading
to multiple episodes of respiratory decompensation requir-
ing noninvasive ventilation was atypical of KHE and raises
the possibility of KLA. However, a review of histologic
features on the biopsy showed features characteristic of
classic KHE (Figs. 3A–C) and not KLA.
The recent addition of mTOR inhibitors to the man-
agement of vascular tumors and malformations has sig-
niﬁcantly improved the therapeutic options for patients,
particularly when a lymphatic component is present.7 The
FIGURE 3. A, Multinodular tumor composed of sheets of spindled cells, well-formed capillary-like vessels and occasional crescent-shaped
vascular spaces. Hematoxylin and eosin stain, ×2 magnification. B, “Glomeruloid” clusters of rounded to epithelioid endothelial cells.
Hematoxylin and eosin stain, ×20 magnification. C, D2-40 (lymphatic marker) mainly stained the neoplastic spindled cells, ×4
magnification.
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mTOR inhibitor sirolimus is an oral medication that can be
taken in the outpatient setting, with signiﬁcantly less side
effects than the previous ﬁrst-line therapies of vincristine
and/or steroids. Sirolimus has been used in the treatment of
KHE associated with KMP, leading to reduction in tumor
size and an increase in platelet counts; however, doses,
duration of therapy, and utility of targeting sirolimus levels
have not been standardized.13,14 Sirolimus has been shown
to inhibit lymphangiogenesis, which in turn decreases pla-
telet trapping.15 Our patient was started on sirolimus at a
dose of 0.8 mg/m2/dose twice daily, targeting serum levels of
5 to 15 μg/L. This dose was based on the publication of the
phase II trial conducted by Adams et al7 which included 57
patients treated with sirolimus for either vascular tumors (13
of which had KHE) or malformations. Adams et al7
reported that all patients with KHE with KMP demon-
strated partial response to sirolimus.
A systematic review of the efﬁcacy and safety of
mTOR inhibitors in the treatment of vascular anomalies
revealed that sirolimus was the most common agent used
and was effective and well tolerated, although dosage was
heterogenous.16 A retrospective review evaluated the
response to sirolimus in patients with vascular tumors and
malformations and found a response rate of 80.4% with
improvement in radiologic imaging and symptom reduction
after a median of 10 weeks.17 A recent multicenter retro-
spective cohort study was conducted in patients with pro-
gressive KHE treated with sirolimus.18 Patients without
KMP were treated with sirolimus alone and patients with
KMP received sirolimus (0.8 mg/m2 twice daily, adjusted to
attain trough levels of 10 to 15 ng/mL) and prednisolone.18
In all patients on dual therapy, prednisolone was tapered
and patients continued on sirolimus treatment alone.18
Overall, the above studies have shown that the response to
sirolimus is not immediate, and that the duration of therapy
is not known. Furthermore, it is not known what doses are
required or what is the appropriate sirolimus target range.
These questions regarding sirolimus use in KHE remain to
be explored.
Our patient was started on sirolimus following MRI
imaging consistent with KHE. After 2 months of being on
sirolimus therapy he was no longer severely thrombocyto-
penic, and a 6-month repeat MRI showed signiﬁcant
reduction in the size of the mass (Fig. 4). This case outlines
the importance of aggressively searching for an underlying
vascular tumor even without skin ﬁndings in the presence of
suspected KMP, and utilizing speciﬁc imaging modalities in
diagnosing a vascular tumor. Our patient had an overall
good, but not immediate, response to sirolimus, though there
is no consensus in the literature for the optimal duration of
treatment, or the long-term prognosis of KHE once treat-
ment is discontinued. Further studies investigating these
aspects are key for optimal management of these patients.
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